615 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Breakthru Advisory Services LLC

Breakthru Advisory Services LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 615 shares of the company's stock, valued at approximately $475,000. Eli Lilly and Company accounts for 0.4% of Breakthru Advisory Services LLC's portfolio, making the stock its 29th biggest holding.

A number of other large investors also recently modified their holdings of LLY. GTS Securities LLC grew its position in Eli Lilly and Company by 123.9% during the fourth quarter. GTS Securities LLC now owns 4,139 shares of the company's stock valued at $3,195,000 after acquiring an additional 21,480 shares during the last quarter. Fourth Dimension Wealth LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $973,000. Stonebridge Financial Planning Group LLC raised its position in shares of Eli Lilly and Company by 6.4% in the 4th quarter. Stonebridge Financial Planning Group LLC now owns 1,802 shares of the company's stock worth $1,391,000 after purchasing an additional 109 shares during the last quarter. Vise Technologies Inc. raised its position in shares of Eli Lilly and Company by 57.2% in the 4th quarter. Vise Technologies Inc. now owns 11,896 shares of the company's stock worth $9,184,000 after purchasing an additional 4,330 shares during the last quarter. Finally, Retirement Planning Group LLC raised its position in shares of Eli Lilly and Company by 5.2% in the 4th quarter. Retirement Planning Group LLC now owns 364 shares of the company's stock worth $281,000 after purchasing an additional 18 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Price Performance

LLY traded up $11.87 during trading on Tuesday, reaching $725.58. The stock had a trading volume of 1,683,681 shares, compared to its average volume of 3,615,191. The firm has a market capitalization of $687.66 billion, a price-to-earnings ratio of 61.91, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a 50 day moving average of $786.82 and a two-hundred day moving average of $802.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.58 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. Eli Lilly and Company's dividend payout ratio is 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.